<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337606</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-046</org_study_id>
    <nct_id>NCT04337606</nct_id>
  </id_info>
  <brief_title>Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor</brief_title>
  <official_title>Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor : An Open-label Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed
      after chimeric antigen receptor T cells infusion. The purpose is to evaluate the safety and
      efficacy of the treatment with chidamide in combination with decitabine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 4, 2020</start_date>
  <completion_date type="Anticipated">April 4, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>2 years</time_frame>
    <description>CR rate assess by investigators per the 2014 Lugano classification rate of subjects achieved complete response in all evaluable subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>chidamide in combination with decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chidamide 10mg/day, days 1-5, 20mg/day, day 8, 11,15, 18; decitabine 10 mg/day, days 1-5, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>decitabine in combination with Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>decitabine 10 mg/day, days 1-5, every 3 weeks; camrelizumab 200mg d6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can Induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance; Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.</description>
    <arm_group_label>chidamide in combination with decitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1(DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.</description>
    <arm_group_label>chidamide in combination with decitabine</arm_group_label>
    <arm_group_label>decitabine in combination with Camrelizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab is a humanized anti-PD-1 monoclonal antibody.</description>
    <arm_group_label>decitabine in combination with Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have histological confirmation of Non-Hodgkin lymphoma (NHL) and
             relapsed after chimeric antigen receptor T cells infusion.

          2. 18 to 65 years of age.

          3. ECOG performance of less than 2.

          4. Life expectancy of at least 3 months.

          5. Subjects with lymphoma must have at least one measureable new lesion &gt;1.5cm as defined
             by lymphoma response criteria.

          6. Subjects must have relapsed after chimeric antigen receptor T cells infusion without
             any intervention treatment prior to Day 1.

          7. Subjects must have adequate marrow, live, renal and heart functions.

        Exclusion Criteria:

          1. Subjects with any autoimmune disease or history of syndrome that requires
             corticosteroids or immunosuppressive medications.

          2. Serious uncontrolled medical disorders or active infections, pulmonary infection
             especially.

          3. Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in one
             month .

          4. Prior organ allograft.

          5. Women who are pregnant or breastfeeding.

          6. Women with a positive pregnancy test on enrollment or prior to investigational product
             administration.

          7. Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (eg, infectious disease) illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong D Han, Doctor</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>C, Doctor</last_name>
    </contact_backup>
    <investigator>
      <last_name>Weidong Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yajing Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chunmeng Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>zhiqiang Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qian Mei</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuan Tong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanren Dai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Nie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 4, 2020</last_update_submitted>
  <last_update_submitted_qc>April 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

